220 related articles for article (PubMed ID: 26022230)
1. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
Lange SA; Jung J; Jaeck A; Hitschold T; Ebner B
Cardiovasc Toxicol; 2016 Apr; 16(2):193-206. PubMed ID: 26022230
[TBL] [Abstract][Full Text] [Related]
2. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
[TBL] [Abstract][Full Text] [Related]
3. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
Mele D; Malagutti P; Indelli M; Ferrari L; Casadei F; Da Ros L; Pollina A; Fiorencis A; Frassoldati A; Ferrari R
Ultrasound Med Biol; 2016 Jan; 42(1):125-32. PubMed ID: 26603736
[TBL] [Abstract][Full Text] [Related]
5. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.
Lange SA; Ebner B; Wess A; Kögel M; Gajda M; Hitschold T; Jung J
Clin Res Cardiol; 2012 Jun; 101(6):415-26. PubMed ID: 22249492
[TBL] [Abstract][Full Text] [Related]
6. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
8. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.
Cadeddu C; Piras A; Dessì M; Madeddu C; Mantovani G; Scartozzi M; Hagendorff A; Colonna P; Mercuro G
Int J Cardiovasc Imaging; 2017 Feb; 33(2):197-207. PubMed ID: 27696298
[TBL] [Abstract][Full Text] [Related]
9. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
10. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Hui R; Boyd A; Harnett PR; Meikle SR; Clarke J; Thomas L
Eur J Echocardiogr; 2011 Dec; 12(12):945-52. PubMed ID: 21965152
[TBL] [Abstract][Full Text] [Related]
11. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
12. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
[TBL] [Abstract][Full Text] [Related]
13. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
[TBL] [Abstract][Full Text] [Related]
14. Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.
Moustafa S; Murphy K; Nelluri BK; Northfelt D; Shah P; Lee H; Wilansky S; Naqvi TZ; Meyer S; Mookadam F
Echocardiography; 2016 Mar; 33(3):406-15. PubMed ID: 26498324
[TBL] [Abstract][Full Text] [Related]
15. [Trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer].
Shen S; Xu Y; Sun Q; Wang C; Zhou Y; Mao F; Guan J; Lin Y; Wang X; Han S
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):132-6. PubMed ID: 24796463
[TBL] [Abstract][Full Text] [Related]
16. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
Negishi K; Negishi T; Haluska BA; Hare JL; Plana JC; Marwick TH
Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):324-31. PubMed ID: 24057661
[TBL] [Abstract][Full Text] [Related]
17. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist.
Mornoş C; Petrescu L
Can J Physiol Pharmacol; 2013 Aug; 91(8):601-7. PubMed ID: 23889668
[TBL] [Abstract][Full Text] [Related]
18. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
20. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
